Abstract
Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system. Spontaneous restoration of myelin after demyelination occurs, but its efficiency declines during disease progression. Efficient myelin repair requires fine-tuning inflammatory responses by brain-resident microglia and infiltrating macrophages. Accordingly, promising therapeutic strategies aim at controlling inflammation to promote remyelination. Polysialic acid (polySia) is a polymeric glycan with variable chain lengths, presented as a posttranslational modification on select protein carriers. PolySia emerges as a negative regulator of inflammatory microglia and macrophage activation and has been detected on oligodendrocyte precursors and reactive astrocytes in multiple sclerosis lesions. As shown recently, polySia-modified proteins can also be released by activated microglia, and the intrinsically released protein-bound and exogenously applied free polySia were equally able to attenuate proinflammatory microglia activation via the inhibitory immune receptor Siglec-E. In this study, we explore polySia as a candidate substance for promoting myelin regeneration by immunomodulation. Lysophosphatidylcholine-induced demyelination of organotypic cerebellar slice cultures was used as an experimental model to analyze the impact of polySia with different degrees of polymerization (DP) on remyelination and inflammation. In lysophosphatidylcholine-treated cerebellar slice cultures, polySia-positive cells were abundant during demyelination but largely reduced during remyelination. Based on the determination of DP24 as the minimal polySia chain length required for the inhibition of inflammatory BV2 microglia activation, pools with short and long polySia chains (DP8–14 and DP24–30) were generated and applied to slice cultures during remyelination. Unlike DP8–14, treatment with DP24–30 significantly improved remyelination, increased arginase-1-positive microglia ratios, and reduced the production of nitric oxide in wildtype, but not in Siglec-E-deficient slice cultures. In vitro differentiation of oligodendrocytes was not affected by DP24–30. Collectively, these results suggest a beneficial effect of exogenously applied polySia DP24–30 on remyelination by Siglec-E-dependent microglia regulation.
Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that leads to the demyelination of the white matter and axonal damage (Haines et al., ; Lassmann, ; Correale et al., ). Demyelinating lesions also increase in the white matter of the cerebellar cortex, and more than 35% of the total cerebellar cortical area can be affected in progressive MS forms (Kutzelnigg et al., , ; Gilmore et al., ), causing acute and chronic symptoms such as tremor, ataxia, and dysarthria (Wilkins, ). Spontaneous remyelination in MS lesions occurs, mediated by oligodendrocytes arising from the differentiation of oligodendrocyte progenitor cells (OPCs), but this is highly limited and incomplete (Franklin and Simons, ). Successful strategies for complete remyelination, in which denuded axons are restored by isolating compact myelin, are currently not available. For the prevention and possibly even reversion of motor dysfunctions and total MS-associated disability, improving remyelination is a promising therapeutic avenue (Franklin and Simons, ).
In recent years, numerous studies indicate that besides OPC-autonomous mechanisms of remyelination, microglia, and astrocytes mediate immunomodulation and tissue repair (Franklin and Simons, ). In particular, activated microglia together with infiltrating monocyte-derived macrophages engage in proinflammatory crosstalk and phagocytosis of myelin debris during demyelination, while during remyelination, anti-inflammatory polarization of microglia might contribute to tissue repair and immune balance (Mahmood and Miron, ).
PolySia is the α-2,8-linked homopolymer of the acidic sugar 5-N-acetylneuraminic acid, the most common sialic acid found in the brain (Schauer, ). PolySia chains of variable lengths occur as posttranslational glycan modification of only a few protein carriers, most prominently the neural cell adhesion molecule NCAM (Rutishauser, ; Schnaar et al., ; Thiesler et al., ). PolySia-NCAM is a major regulator of cell surface interactions during brain development and can be presented on both neurons and glial cells, such as OPCs and some types of astrocytes (Rutishauser, ; Schnaar et al., ; Thiesler et al., ).
Notably, transient expression of polySia-NCAM has been detected on reactive astrocytes and OPCs in lysophosphatidylcholine (LPC)-induced lesions of the mouse spinal cord (Nait Oumesmar et al., ) and in active human MS lesions (Nait-Oumesmar et al., ). Furthermore, polySia is present in demyelinated axons in MS lesions but not in remyelinated axons in shadow plaques, which may prevent successful remyelination (Charles et al., ). A dual role of polySia for myelin repair has been derived from the analyses of remyelination after cuprizone-induced demyelination. In the cuprizone model, loss of either of the two polySia synthesizing enzymes, ST8SIA2 or ST8SIA4, compromises (ST8SIA2) or improves (ST8SIA4) remyelination (Koutsoudaki et al., ; Werneburg et al., ). These seemingly contradictory outcomes could be explained by the sequential expression of the two polysialyltransferases and cell-autonomous effects of polySia-NCAM, promoting early stages but inhibiting late stages of OPC differentiation (Werneburg et al., ).
In contrast to the presentation of polySia-NCAM at the cell surface, microglia and macrophages can accumulate an intracellular, Golgi-confined pool of polySia on two other carrier proteins, neuropilin-2 (NRP2) and E-selectin ligand-1 (ESL-1) (Werneburg et al., ). As shown in vitro, this pool of polysialylated proteins can be released in response to inflammatory activation and dampens the inflammatory response in a negative feedback loop mediated by the inhibitory immune receptor sialic acid-binding Ig-like lectin-E (Siglec-E) (Werneburg et al., , ; Thiesler et al., ). These data suggest a role of the polySia-Siglec-E axis in balancing microglial activation. Importantly, inhibition of inflammatory microglia activation can also be achieved by the administration of protein-free, soluble polySia with an average chain length (degree of polymerization, DP) of ~50, but not by oligosialic acid with a DP of 3 (Thiesler et al., ). Similarly, polySia with an average DP of 20 (avDP20) could inhibit inflammatory microglia and macrophage activation via the human polySia receptor Siglec-11 and was successfully applied to ameliorate laser-induced retina damage and lipopolysaccharide-induced neurodegeneration in transgenic mice expressing Siglec-11 in mononuclear phagocytes (Shahraz et al., ; Karlstetter et al., ; Liao et al., ). However, besides its Siglec-dependent inhibition of microglia and macrophages, polySia avDP20 seems capable of directly interacting with properdin, a positive regulator of the alternative complement pathway, to reduce properdin-mediated complement deposition (Liao et al., ).
In the context of myelin repair, the effects of protein-free, soluble polySia have not yet been studied. In this study, we used cerebellar organotypic slice cultures (OSCs), a widely exploited model system to screen compounds for myelin repair (Sekizar and Williams, ), with the aim to elucidate the potential of exogenously administered polySia to improve remyelination.
Materials and methods
Animals
Animals were bred in the central animal facility of Hannover Medical School (MHH) and underwent routine cage maintenance. Microbiological monitoring was performed according to the Federation of European Laboratory Animal Science Associations (FELASA) recommendations (Guillen, ). All procedures were approved by the Lower Saxony State Office for Consumer Protection and Food Safety (LAVES; permission no. 19/3277) and were performed according to international guidelines on the use of laboratory animals.
For pilot experiments, 8–10-week-old C57BL/6J breeding couples were purchased from Charles River Laboratories (Sulzfeld, Germany), and their offspring were killed at postnatal days 9 to 11 (P9–11) to generate OSCs. For primary OPC cultures, Sprague-Dawley rats, purchased from Charles River, were bred at MHH, and dissected brains of P0–P3 neonates were provided by A. Guba-Quint (Cardiology, MHH). Siglec-E knockout mice (B6;129S5-Siglecetm1Lex/Mmucd, MMRC), obtained from the Mutant Mouse Resource & Research Center (MMRRC, UC Davis, CA), were backcrossed with C57BL/6 mice for at least 10 generations (Andes et al., ). Homozygous Siglece−/− and Siglece+/+ matings were derived from common heterozygous founders.
Genotyping was performed using the following primers: 5′-CTTCCCTATGCCCTAGAACCAT-3′ (DNA287-23) and 5′-CCCTAGGAATGCTCGTCCCGA-3′ (GT-IRES), leading to a 548 bp fragment indicative for the Siglece knockout allele, and 5′-GGCCAGTCACTGCGTCTCAT-3′ (DNA287-19) and 5′-CAGTAAGGTTTTGGATAGCCAG-3′ (DNA287-29), resulting in a 414 bp fragment indicative for the Siglece wildtype allele.
Organotypic slice cultures
OSCs from the murine cerebellum were prepared as previously described (Stoppini et al., ). Briefly, 350 μm thick parasagittal brain slices from postnatal 9 to 11-day-old (P9–11) C57BL/6J, Siglece−/−, or Siglece+/+ mice were cut using a vibratome (Leica VT1000 S Vibrating blade microtome). The slices were cultured on Millicell-CM culture well inserts in 6-well plates (Millipore, Darmstadt, Germany) with a medium containing 50% minimum essential medium (Invitrogen, Carlsbad, USA), 25% Hank's balanced salt solution (Lonza, Verviers, Belgium), 25% horse serum (Invitrogen, Carlsbad, CA), 1% penicillin/streptomycin, 6.5 mg/ml of glucose (Invitrogen, Carlsbad, USA), and 2 mM L-glutamine (Thermo Fisher Scientific, Waltham, USA) for a maximum of 14 days at 37°C and 5% CO2. Per animal, eight OSCs were prepared and evenly assigned to the four different treatment groups (see Results section). Per cell culture well, four OSCs from two different animals with matched Siglece genotypes were co-cultured on one cell culture insert.
The slices were cultured for 7 days to allow full developmental myelination. To elaborate on the effect of exogenously added soluble polySia on remyelination, cell culture wells containing cerebellar slices were demyelinated by incubation with LPC (0.5 mg/ml) for 15–17 h after 7 days in vitro (DIV). PolySia fractions of defined DP (see below) were applied as detailed in the Results section. At 14 DIV, supernatants were collected and OSCs were fixed as described below (for timeline, see Figure 1).
Figure 1
OPC cultures
OPCs were harvested from mixed glial cultures derived from eight P0–P4 Sprague-Dawley rats per experiment, as described previously (Gingele et al., ), and seeded onto poly-L-lysine-coated glass coverslips in a 24-well plate (105 cells per coverslip). OPCs were incubated for 4 h in oligodendrocyte medium (KnockOutTM DMEM/F-12, supplemented with 2 % StemPro® Neural Supplement, and 1% GlutaMAX™ Supplement; all Gibco, Karlsruhe, Germany) with an additional 20 ng/ml of EGF, 20 ng/ml of FGF-1, and 10 ng/ml of PDGF-AA (all Thermo Fisher Scientific) for proliferation (Gingele et al., ). Following washing with PBS, OPCs were incubated for 48 h in 300 μl of oligodendrocyte medium devoid of growth factors, supplemented without or with 5 μg/ml of polySia as specified in the Results section.
Per OPC preparation, a purity of >95% was determined by double-staining of one differentiated, but otherwise, untreated culture for PDGFR-α (recombinant rabbit mAb, Abcam, Cambridge, UK, 1:200) to detect cells of the oligodendrocyte lineage and for GFAP (mouse monoclonal IgG1, Millipore, Burlington, MA, USA, 1:200) to detect astrocytes (< 2%). In addition, one untreated culture was stained for PDGFR-α together with a CD11b-specific antibody (mouse IgG2a, clone OX-42, Bio-Rad, Hercules, CA, USA, 1:200) to demonstrate < 3% of contamination with microglia. To control cell proliferation, one well of each treatment group was labeled with Alexa Fluor 488-labeled mouse anti–Ki-67 mAb (mouse IgG1, BD Pharmingen, Heidelberg, Germany, 1:100). A rate of 97% Ki-67-positive cells was uniformly observed for all OPC preparations and treatment groups.
BV2 cell culture
The murine microglial cell line BV2 was cultured as described previously (Thiesler et al., ). For inflammatory activation, 5 × 104 cells were seeded in 96-well plates, treated with an activation mix consisting of lipopolysaccharide (LPS, Sigma Aldrich, St. Louis, MO, USA, #L3129, 10 ng/ml), LPS-binding protein (Icell, #C370, 50 ng/ml), and zymosan (InvivoGen, San Diego, CA, USA, #tlrl-zyn, 10 μg/ml) in 200 μl of serum-free medium, and cultured for 24 h in the presence or absence of polySia as specified with the respective results.
Generation of polySia fractions
PolySia fractions of defined DP were generated by the limited hydrolysis of colominic acid sodium salt (Sigma Aldrich, #C5762) in 100 mM acetic acid. Subsequently, pH was adjusted to 10.5 with NaOH, followed by 48 h incubation at 4°C. Fractions with single DPs were separated as described (Thiesler et al., ), and fractions of interest were pooled, desalted by size exclusion applying a 2 kDa cutoff for the isolation of fractions with DP8-14 or a 3 kDa cutoff for the isolation of fractions with DP>14, and followed by lyophilization and storage at −20°C. The DPs of the fractions were assigned using α2,8-linked tetrasialic acid (DP4) as a standard (Nacalai Tesque, Kyoto, Japan, #00642-42).
Whole-mount immunohistochemistry
OSCs were fixed for 2 h in 4% paraformaldehyde (PFA), followed by washing with PBS and permeabilization for 2 h in PBS with 0.6 % Triton X-100 (Serva, Heidelberg, Germany). After blocking with PBS-containing 0.3 % Triton X-100 and 5 % normal goat serum (NGS) for at least 4 h, the slices were incubated with primary antibodies diluted in PBS with 0.3% Triton X-100 for 48 h by 4°C. After repeated PBS washing, slices were incubated with secondary antibody in PBS/0.3 % Triton X-100 overnight at 4°C. Slices were washed three times with PBS and immediately mounted in VECTASHIELD with 4,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA).
The following primary monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) were used: myelin oligodendrocyte glycoprotein (MOG)-specific hybridoma supernatant (generated from hybridoma cells provided by Christopher Linington, University of Glasgow, UK, 1:2), ionized calcium-binding adaptor molecule 1 (IBA-1)-specific rabbit pAb (Wako Chemicals, Neuss, Germany, 1.200), arginase-1 (ARG-1)-specific goat pAB (Abcam, Cambridge, UK, 1:200), and polySia-specific mouse mAb 735 (Frosch et al., ), produced in-house as described (Werneburg et al., ) (2 μg/ml). Secondary antibodies were goat anti-mouse Alexa-550, goat anti-rabbit Alexa-488, and donkey anti-goat Alexa-555 (all from Invitrogen).
Immunocytochemistry
After treatment, OPC cultures were repeatedly washed with PBS, and living cells were incubated for 30 min at 37°C with a differentiation medium containing 1:2 diluted mouse hybridoma supernatants with equal amounts of mouse anti-A2B5 (IgMμ, clone 105) and mouse anti-galactocerebroside (GALC, IgG3, clone IC-07, both from the European Collection of Authenticated Cell Cultures, ECACC, Salisbury, UK). Cells were fixed for 15 min with 4% PFA, incubated for 45 min with Alexa Fluor 488-conjugated goat anti-mouse IgG3, 1:500, and Alexa Fluor 555-conjugated goat anti-mouse IgMμ, 1:500 (both Thermo Fisher Scientific), and mounted in Mowiol® (Merck Millipore, Darmstadt, Germany) with DAPI (Sigma Aldrich, 1:1000).
Microscopy, image acquisition, morphometry, and cell counting
Images were acquired on an LSM 900 confocal microscope equipped with an Airyscan 2 detector and Zen 2012 (blue edition) software (Carl Zeiss Microscopy, Göttingen, Germany). For morphometric evaluation of MOG labeling, images of 3–4 individual lobules within the cerebellar cortex of each OSC, and from two OSCs per animal, were evaluated, after background subtraction, by calculating the percentage of immunopositive areas in frames of 350 × 350 μm using ImageJ Software (Fiji, U. S. National Institutes of Health, Bethesda, Maryland). The numbers of IBA-1 and ARG-1 immunopositive cells within the white matter and the internal granular cell layer of a cerebellar lobule were quantified in 3–4 lobules per OSC and from two OSCs per animal, using the bioimaging analysis platform QuPath (Bankhead et al., ), in which cells were segmented and subsequently classified. The cell segmentation model was trained under visual control on a set of five images per condition using the deep learning-based StarDist library (Schmidt et al., ).
Immunopositive cells in OPC cultures were counted at 20x magnification using an Olympus BX41 fluorescence microscope and cellSens software (Olympus, Tokyo, Japan).
Nitric oxide determination
To assess nitric oxide (NO) production, nitrite, the stable reaction product of NO, was determined by the colorimetric Griess assay. Supernatants from the culture slices were collected per well, cleaned by precipitation with acetonitrile (80%v/v), and centrifuged at 16.000xg (15 min, 4°C). The supernatants were dried at RT. After rehydration in 10% of the original volume, the sample was mixed 1:1 with Griess reagent, prepared in-house as described (Thiesler et al., ), and incubated for 20 min (RT). Absorbance at 540 nm was determined against a reference wavelength of 620 nm, nitrite concentrations were calculated from a standard curve (Promega, Wisconsin, USA), and values were normalized to the mean of untreated wildtype controls.
Statistical analysis
GraphPad Prism version 8.02 was used for statistical analysis (GraphPad, San Diego, USA). The one- or two-way ANOVA followed by Tukey's post-hoc tests were applied as indicated. Normality and equality of variances were assessed using the Shapiro–Wilk and the Brown–Forsythe test, respectively. To meet the assumption of normal distribution, the ROUT method with a false discovery rate of Q = 1% was used to eliminate four outliers from the determinations of nitrite in OSC supernatants (Figure 4). Values are presented as arithmetic means ± standard error of the mean (SEM). A P-value of < 0.05 was considered statistically significant.
Results
PolySia is transiently elevated during LPC-induced demyelination
Figure 1A illustrates the timeline of LPC-induced OSC de- and remyelination and the experimental treatment scheme. At the onset of the culturing period (P9–11), cerebellar myelination is not yet completed. To permit the progression of developmental myelination, the slices were cultured for 7 days before being treated with 0.5 mg/ml of LPC for 15–17 h, leading to the ablation of white matter at 9 DIV, as illustrated by the absence of staining for MOG, a marker of terminally differentiated myelinating oligodendrocytes (Figure 1B). Spontaneous remyelination was detected at 11 DIV and proceeded until 14 DIV, the endpoint of the study (Figure 1B). Staining for microglia revealed initial activation at 9 DIV, indicated by clustering, process retraction, and adoption of an amoeboid shape, followed by an almost complete reversion to a ramified morphology, indicative of homeostatic microglia (Figure 1C). Compared to untreated controls, the numbers of IBA-1-positive microglia were transiently decreased after LPC treatment. This is in good agreement with previous data, showing a similar decline of microglia due to necroptosis early after LPC application to cerebellar OSCs and prior to the onset of remyelination in mice injected with LPC into the corpus callosum (Lloyd et al., ).
Consistent with the transient polySia expression by astrocytes and OPCs during LPC-induced demyelination of the spinal cord in vivo (Nait Oumesmar et al., ), abundant polySia immunoreactivity was detected in cerebellar lobules during the phase of demyelination (9 DIV), which rapidly declined to low levels at 11 and 14 DIV (Figure 1D). Accordingly, during remyelination and treatment with exogenously applied soluble forms of protein-free polySia, only little intrinsic, cellular polySia was present in the OSCs. Thus, the OSC model appears suited to test the effects of exogenous polySia on remyelination.
PolySia has a critical degree of polymerization to attenuate the inflammatory response of microglia
Aiming at treatment with polySia of defined chain lengths, polySia fractions consisting of defined DPs were separated (Figure 2A) and used to test for the inhibition of LPS-induced NO production as a wellestablished readout for inflammatory activation and the Siglec-E-dependent inhibitory effect of polySia avDP50 in microglial BV2 cells (Thiesler et al., ). As shown in Figure 2B, only polySia fractions with a DP of 24 and more showed efficient inhibition, comparable to the effect of polySia with avDP50. For polySia treatment of OSCs, we used pools consisting of polySia DP24–30, which can inhibit proinflammatory-activated microglia, and DP8–14, which cannot (Figure 2C).
Figure 2
PolySia DP24–30 improves remyelination
Effects of exogenously applied polySia fractions with DP8–14 and DP24–30 on remyelination were analyzed in a pilot experiment with OSCs from wildtype C57BL/6J mice. Morphometric evaluation of MOG revealed a significant improvement in remyelination after the application of DP24–30, while DP8–14 had no effect (Supplementary Figure 1). A comparative approach with Siglece+/+ and Siglece−/− OSCs (Figure 3) reproduced this outcome for the Siglece+/+ groups (Figures 3A, C). In sharp contrast, polySia DP24–30 had no effect on remyelination in Siglece−/− OSCs (Figures 3B, C). As evident in the wildtype C57BL/6J and Siglece+/+ groups (Supplementary Figure 1; Figure 3A), remyelination after the application of DP24–30 was not confined to the white matter but also detected throughout the internal granular and Purkinje cell layers of the cerebellar lobules.
Figure 3
Because the improved remyelination in the presence of polySia DP24–30 was dependent on the presence of the microglia-specific polySia receptor Siglec-E, and because DP8–14, which was not able to inhibit the inflammatory activation of cultured microglia, had no effect, it can be assumed that the impact of polySia DP24–30 is mediated by Siglec-E dependent inhibition of proinflammatory microglia.
PolySia DP24–30 inhibits NO production and augments the fraction of arginase-1-positive microglia during remyelination
NO production is a hallmark of proinflammatory microglia activation and is widely accepted as a mediator of oligodendrocyte cytotoxicity and demyelination in the CNS (Smith and Lassmann, ; Liñares et al., ; Merrill et al., ). Therefore, and to corroborate the assumed inhibitory effect of polySia DP24–30 on inflammatory microglia activation during remyelination, NO production was determined by measuring the stable NO breakdown product nitrite in OSC supernatants at 14 DIV. NO production was significantly increased in LPC-treated cerebellar OSCs derived from C57BL/6J and Siglece+/+ mice and this was completely reverted by treatment with polySia DP24–30, but not with DP8–14 (Supplementary Figure 1 for C57BL/6J, Figure 4 for Siglece+/+, respectively). In the absence of the inhibitory immune receptor Siglec-E, however, NO production was strongly elevated in all treatment groups and neither affected by LPC nor polySia treatment (Figure 4), consistent with results obtained previously for Siglece−/− BV2 microglia (Thiesler et al., ).
Figure 4
We next sought to study the expression of arginase-1 in remyelinating white matter areas. Arginase-1 is an opponent of NO production and a marker of anti-inflammatory, protective microglia, and macrophage phenotypes that are essential for remyelination (Miron et al., ). In contrast to slightly enhanced overall numbers of IBA-1-positive microglia, numbers of IBA-1 and arginase-1 double-positive microglia were dramatically increased in LPC-treated OSCs derived from Siglece+/+ mice and exposed to polySia DP24–30 (Figures 5A, C, D). Again, polySia DP8–14 had no significant impact. Unexpectedly, the numbers of IBA-1 and arginase-1 double-positive cells were significantly higher in untreated Siglece−/− as compared to Siglece+/+ OSCs (Figures 5B, D). This might be linked to the slight, but not significant increase in IBA-1-positive microglia numbers observed in this group (Figure 5C). The simultaneous reduction of the IBA-1-positive and the IBA-1 and arginase-1 double-positive cells in LPC-treated Siglece−/− OSCs supports this assumption. Unlike the strong increase of NO production in all Siglece−/− OSCs irrespective of treatment (see Figure 4), the reduction in cell numbers after LPC treatment indicates that microglia in Siglece−/− OSCs still react to the LPC-induced demyelination. Moreover, an increase in arginase-1-positive cells may counterbalance the increase in NO production by Siglece−/− OSCs during LPC-induced de- and remyelination, which may explain the unaltered level of remyelination in otherwise untreated Siglece−/− OSCs (see Figures 4B, C). Importantly, however, in contrast to Siglece+/+ OSCs, numbers of IBA-1- and arginase-1-positive microglia were not increased in remyelinating Siglece−/− OSCs treated with polySia DP24–30 (Figures 5B–D). Together, these data indicate that polySia DP24–30 not only inhibits the proinflammatory activation of microglia during remyelination but also induces a Siglec-E-dependent shift in polarization toward a protective phenotype that supports remyelination.
Figure 5
PolySia DP24–30 has no direct impact on OPC differentiation
As shown in previous studies, the level of polySia attached to proteins on the surface of OPCs has a direct effect on their differentiation toward mature oligodendrocytes (Werneburg et al., ). Therefore, the observed beneficial effect of soluble polySia DP24–30 on remyelination could also be, at least in part, mediated by a cell-autonomous stimulation of OPC differentiation. To address this possibility, we studied the effect of polySia DP24–30 on the differentiation of primary rat OPC cultures. Differentiation was assessed by monitoring the numbers of immature A2B5-expressing OPCs and mature GALC-expressing oligodendrocytes after 48h in the differentiation medium without or with the addition of polySia fractions (Figure 6).
Figure 6
Compared to untreated controls, polySia DP24–30 had no effect on the total number of cells (Figure 6B) and on the numbers of A2B5-positive OPCs or GALC-positive oligodendrocytes (Figures 6C, D). Unexpectedly, DP8–14 had a negative impact on particularly the numbers of GALC-positive cells. This contrasts with the complete absence of polySia DP8–14-mediated effects on remyelination and microglia polarization.
In summary, these results demonstrate that exogenously applied polySia DP24–30 promotes remyelination and provide strong evidence that this effect is mediated by a Siglec-E-dependent shift from a proinflammatory toward an anti-inflammatory microglia phenotype.
Discussion
PolySia is emerging as a novel regulator of microglia activity, but, so far, its intricate role in developmental myelination and remyelination has been mostly assigned to regulatory functions in OPC differentiation mediated by polySia attached to NCAM at the cell surface (reviewed in Thiesler et al., ). A negative feedback regulation of inflammatory microglia activation by the release of polySia through ectodomain shedding of polySia-NRP2 and polySia-ESL-1, and its perception by the inhibitory immune receptor Siglec-E has been demonstrated in studies with cultured microglia (Werneburg et al., , ; Thiesler et al., ). Evidence that this mechanism may be relevant under pathophysiological conditions in vivo was derived from the identification of polysialylated NRP2 and ESL-1 and the immunohistochemical detection of intracellular polySia accumulations in the Golgi compartment of injury-induced microglia in mouse brain OSCs (Werneburg et al., ) and from the sequence of polySia appearance and disappearance in microglia activated by a cortical stab wound (Thiesler et al., ). Furthermore, the application of soluble, protein-free polySia with avDP20 led to reductions of laser-induced retina damage and lipopolysaccharide-induced neurodegeneration in transgenic mice expressing human Siglec-11 in mononuclear phagocytes (Karlstetter et al., ; Liao et al., ).
These studies provided proof of principle for the potential of therapeutic polySia applications. In the in vivo studies, however, it remained unresolved, which of the competing or complementary polySia interactions with transgenic Siglec-11, endogenous Siglec-E, or, possibly, with properdin reducing complement deposition independent of Siglec-mediated microglia regulation (Shahraz et al., ), were decisive for the improved outcome. In contrast, several lines of evidence indicate that the beneficial impact of polySia on remyelination, as demonstrated in the current study, is mediated by the modulation of microglia activity. First, we demonstrate that only polySia with DP24–30 but not with DP8–14 is able to elicit the observed effect. This is consistent with our finding that DP24 is the critical minimal polySia chain length required to inhibit the inflammatory activation of BV2 microglia under controlled conditions in vitro. Second, the inability of polySia DP24–30 to improve remyelination in OSCs from Siglece−/− mice demonstrates that its effect depends entirely on the presence of Siglec-E, which is a specific immune receptor of cells of the myeloid lineage and therefore confined to microglia as the only resident immune cell population of the brain parenchyma and white matter in OSCs derived from the previously uninjured brain (Zhang et al., ; Linnartz-Gerlach et al., ; Kierdorf et al., ). Third, in remyelinating OSCs, polySia DP24–30 profoundly reduced the production of nitric oxide, a hallmark of proinflammatory microglia activation, and promoted the appearance of arginase-1-positive microglia, indicative of anti-inflammatory polarization, shown to be essential for efficient remyelination (Miron et al., ). Fourth, in contrast to polySia presented at the cell surface, polySia DP24–30 had no effect on the differentiation of primary cultured OPCs.
Unexpectedly, polySia DP8–14 had an adverse impact on the in vitro differentiation of OPCs without affecting cell numbers. At first sight, this appears consistent with the need to downregulate polySia during OPC differentiation toward myelinating oligodendrocytes, but this has been assigned to an inhibitory effect of polySia on myelin formation by steric and electrostatic cell surface repulsion which is unlikely to be conveyed by soluble, short but not long polySia fragments (Fewou et al., , ; Bakhti et al., ). Furthermore, polySia DP8–14 had no inhibitory impact on the partial remyelination of cerebellar OSCs within 7 days after LPC-induced demyelination. However, the short, soluble polySia fragments may interfere with the promotion of OPC differentiation by endogenous or forced expression of polySia on the OPC surface (Werneburg et al., ). Based on experiments with OPCs lacking the polysialyltransferase ST8SIA2, it has been hypothesized that the presence of polySia on OPCs promotes their transition to oligodendrocytes by modulating ligand binding and activation of receptors such as the platelet-derived growth factor receptor alpha (PDGFRα) (Szewczyk et al., ). Downstream signaling of PDGFRα is decisive for OPC proliferation but the receptor is rapidly internalized upon ligand binding, downregulated during oligodendrocyte differentiation, and absent on mature oligodendrocytes (Fekete and Nishiyama, ). Possibly, the short soluble polySia fragments interfere with this process, but the observed effect of polySia DP8–14 on OPC differentiation under in vitro conditions requires further investigation.
Numerous studies demonstrate that a shift of microglia polarization from a proinflammatory toward an anti-inflammatory phenotype supports remyelination, pinpointing microglia as an attractive therapeutic target (Franklin and Simons, ; Mahmood and Miron, ). The underlying mechanisms are not entirely clear, but, as shown in cerebellar OSCs, involve microglial secretion of growth factors such as activin-A, which contributes to remyelination by directly activating activin receptor signaling on OPCs (Miron et al., ). In contrast, indirect mechanisms via modulation of astrocyte activity appear unlikely (Gingele et al., ).
There have been many successes in the treatment of MS, but so far all licensed therapeutics aim to modulate the peripheral immune system (Baecher-Allan et al., ; Derfuss et al., ). Some experimental approaches have addressed remyelination in MS (Gingele and Stangel, ); however, no treatment addresses microglia specifically, although there are suggestions that drugs such as teriflunomide may, in addition to the effect on lymphocytes, modulate oligodendrocytes and microglia (Wostradowski et al., ; Göttle et al., ). Direct modulation of microglia may be an attractive approach to support endogenous myelin repair by an additional mode of action combined with the immunomodulation of the peripheral immune system.
A limitation of our study is that it focused on a model of remyelination that is not reflecting the autoimmune origin of MS. On the other hand, only this approach allows a clear dissection of the underlying mechanism with respect to the remyelination process. Furthermore, there is a need to close the putative translational gap between the mouse model and the human situation concerning differences in the polySia responsive inhibitory Siglec receptors. Pending questions concern the minimal chain length required for polySia interactions with human Siglec-11 as compared to murine Siglec-E. Furthermore, it remains open, if polySia chains longer than DP14 and shorter than DP24 may have additional Siglec-independent effects on remyelination, such as interference with complement activation by properdin, as suggested for polySia avDP20 (Shahraz et al., ). Another limitation concerns the question of the role of Siglec-E during spontaneous remyelination in LPC-treated OSCs. The comparable level of remyelination in otherwise untreated Siglece+/+ and Siglece−/− OSCs observed at 14 DIV could be the result of a balance between positive and negative Siglec-E-mediated effects and it will need more extended, longitudinal comparisons to answer this question.
Taken together, this study provides strong evidence for the crucial role of the polySia-Siglec axis in microglial immune balance with beneficial effects on the remyelination process. Based on the profile of polySia chain lengths that are able to modulate microglia activity and polarization, we suggest the controlled application of polySia DP24–30 as a promising strategy to improve myelin repair.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was reviewed and approved by Lower Saxony State Office for Consumer Protection and Food safety (LAVES; permission no. 19/3277).
Author contributions
HT, HH, L-JS, MS, and VG: conceptualization. L-JS, VG, HT, LG, and TM: methodology. L-JS, HT, and LG: data acquisition. L-JS, HT, TM, and HH: data analysis and interpretation. L-JS, HT, and HH: writing—original draft. L-JS, HT, HH, VG, LG, TM, and MS: writing—review. All authors contributed to the article and approved the submitted version.
Funding
This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 324633948, 43223629, and 409784463 (DFG grants Hi 678/9-3, Hi 678/10-1, and Hi 678/10-2, FOR2953 to HH), and by Sanofi-Aventis Deutschland GmbH to L-JS and VG. This publication is funded by the Deutsche Forschungsgemeinschaft (DFG) as part of the Open Access Publikationskosten program. None of the funders were involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Acknowledgments
The authors gratefully acknowledge the excellent technical assistance of Patricia Zarnovican, Kerstin Flächsig-Schulz, and Ulrike Peters-Bernard.
Conflict of interest
HT and HH have filed an international patent application on “Polysialic acid and derivatives thereof, pharmaceutical composition and method of producing Polysialic acid,” WO2020025653A2. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2023.1207540/full#supplementary-material
References
1
AndesF. T.AdamS.HahnM.AustO.FreyS.GrueneboomA.et al. (2021). The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption. Bone143, 115665. 10.1016/j.bone.2020.115665
2
Baecher-AllanC.KaskowB. J.WeinerH. L. (2018). Multiple sclerosis: mechanisms and immunotherapy. Neuron97, 742–768. 10.1016/j.neuron.2018.01.021
3
BakhtiM.SnaideroN.SchneiderD.AggarwalS.MobiusW.JanshoffA.et al. (2013). Loss of electrostatic cell-surface repulsion mediates myelin membrane adhesion and compaction in the central nervous system. Proc. Natl. Acad. Sci. U S A110, 3143–3148. 10.1073/pnas.1220104110
4
BankheadP.LoughreyM. B.FernándezJ. A.DombrowskiY.McArtD. G.DunneP. D.et al. (2017). QuPath: open source software for digital pathology image analysis. Sci. Rep.7, 16878. 10.1038/s41598-017-17204-5
5
CharlesP.ReynoldsR.SeilheanD.RougonG.AigrotM. S.NiezgodaA.et al. (2002). Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis?Brain125, 1972–1979. 10.1093/brain/awf216
6
CorrealeJ.MarrodanM.YsrraelitM. C. (2019). Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines7, 14. 10.3390/biomedicines7010014
7
DerfussT.MehlingM.PapadopoulouA.Bar-OrA.CohenJ. A.KapposL. (2020). Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol.19, 336–347. 10.1016/S1474-4422(19)30391-6
8
FeketeC. D.NishiyamaA. (2022). Presentation and integration of multiple signals that modulate oligodendrocyte lineage progression and myelination. Front. Cell Neurosci.16, 1041853. 10.3389/fncel.2022.1041853
9
FewouS. N.RamakrishnanH.BussowH.GieselmannV.EckhardtM. (2007). Down-regulation of polysialic acid is required for efficient myelin formation. J. Biol. Chem. 282, 16700–16711. 10.1074/jbc.M610797200
10
FewouS. N.RöckleI.HildebrandtH.EckhardtM. (2019). Transgenic overexpression of polysialyltransferase ST8SiaIV under the control of a neuron-specific promoter does not affect brain development but impairs exploratory behavior. Glycobiology29, 657–668. 10.1093/glycob/cwz040
11
FranklinR. J. M.SimonsM. (2022). CNS remyelination and inflammation: from basic mechanisms to therapeutic opportunities. Neuron110, 3549–3565. 10.1016/j.neuron.2022.09.023
12
FroschM.GorgenI.BoulnoisG. J.TimmisK. N.Bitter-SuermannD. (1985). NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc. Natl. Acad. Sci. U S A82, 1194–1198. 10.1073/pnas.82.4.1194
13
GilmoreC. P.DonaldsonI.B.öLOwensT.LoweJ.EvangelouN. (2009). Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry.80, 182–187. 10.1136/jnnp.2008.148767
14
GingeleS.MerkelL.PrajeethC. K.KronenbergJ.von HoevelF. F.SkripuletzT.et al. (2019). Polarized microglia do not influence oligodendrocyte lineage cells via astrocytes. Int. J. Dev. Neurosci.77, 39–47. 10.1016/j.ijdevneu.2019.01.006
15
GingeleS.StangelM. (2020). Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis. Expert Opin. Investigat. Drugs29, 583–594. 10.1080/13543784.2020.1762567
16
GöttleP.GrohJ.ReicheL.GruchotJ.RychlikN.WernerL.et al. (2023). Teriflunomide as a therapeutic means for myelin repair. J. Neuroinflamm.20, 7. 10.1186/s12974-022-02686-6
17
GuillenJ. (2012). FELASA guidelines and recommendations. J. Am. Assoc. Lab. Anim. Sci.51, 311–321.
18
HainesJ. D.IngleseM.CasacciaP. (2011). Axonal damage in multiple sclerosis. Mt Sina.i J. Med.78, 231–243. 10.1002/msj.20246
19
KarlstetterM.KopatzJ.AslanidisA.ShahrazA.CaramoyA.Linnartz-GerlachB.et al. (2017). Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina. EMBO Mol. Med.9, 154–166. 10.15252/emmm.201606627
20
KierdorfK.MasudaT.JordãoM. J. C.PrinzM. (2019). Macrophages at CNS interfaces: ontogeny and function in health and disease. Nat. Rev. Neurosci.20, 547–562. 10.1038/s41583-019-0201-x
21
KoutsoudakiP. N.HildebrandtH.GudiV.SkripuletzT.SkuljecJ.StangelM. (2010). Remyelination after cuprizone induced demyelination is accelerated in mice deficient in the polysialic acid synthesizing enzyme St8siaIV. Neuroscience171, 235–244. 10.1016/j.neuroscience.2010.08.070
22
KutzelniggA.Faber-RodJ. C.BauerJ.LucchinettiC. F.SorensenP. S.LaursenH.et al. (2007). Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol.17, 38–44. 10.1111/j.1750-3639.2006.00041.x
23
KutzelniggA.LucchinettiC. F.StadelmannC.BrückW.RauschkaH.BergmannM.et al. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain128, 2705–2712. 10.1093/brain/awh641
24
LassmannH. (2018). Multiple sclerosis pathology. Cold Spring. Harb. Perspect. Med.8, a028936. 10.1101/cshperspect.a028936
25
LiaoH.WinklerJ.WißfeldJ.ShahrazA.KlausC.NeumannH. (2021). Low molecular weight polysialic acid prevents lipopolysaccharide-induced inflammatory dopaminergic neurodegeneration in humanized SIGLEC11 transgenic mice. Glia69, 2845–2862. 10.1002/glia.24073
26
LiñaresD.TaconisM.MañaP.CorrechaM.FordhamS.StaykovaM.et al. (2006). Neuronal nitric oxide synthase plays a key role in CNS demyelination. J. Neurosci.26, 12672–12681. 10.1523/JNEUROSCI.0294-06.2006
27
Linnartz-GerlachB.KopatzJ.NeumannH. (2014). Siglec functions of microglia. Glycobiology24, 794–799. 10.1093/glycob/cwu044
28
LloydA. F.DaviesC. L.HollowayR. K.LabrakY.IrelandG.CarradoriD.et al. (2019). Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat. Neurosci.22, 1046–105210.1038/s41593-019-0418-z
29
MahmoodA.MironV. E. (2022). Microglia as therapeutic targets for central nervous system remyelination. Curr. Opin. Pharmacol.63, 102188. 10.1016/j.coph.2022.102188
30
MerrillJ. E.HanakS.PuS. F.LiangJ.DangC.Iglesias-BregnaD.et al. (2009). Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J. Neurol.256, 89–103. 10.1007/s00415-009-0075-3
31
MironV. E.BoydA.ZhaoJ. W.YuenT. J.RuckhJ. M.ShadrachJ. L.et al. (2013). M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci.16, 1211–1218. 10.1038/nn.3469
32
Nait OumesmarB.VignaisL.Duhamel-ClerinE.Avellana-AdalidV.RougonG.Baron-Van EvercoorenA. (1995). Expression of the highly polysialylated neural cell adhesion molecule during postnatal myelination and following chemically induced demyelination of the adult mouse spinal cord. Eur. J. Neurosci.7, 480–491. 10.1111/j.1460-9568.1995.tb00344.x
33
Nait-OumesmarB.Picard-RieraN.KerninonC.DeckerL.SeilheanD.HoglingerG. U.et al. (2007). Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc. Natl. Acad. Sci. U S A104, 4694–4699. 10.1073/pnas.0606835104
34
RutishauserU. (2008). Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat. Rev. Neurosci.9, 26–35. 10.1038/nrn2285
35
SchauerR. (2009). Sialic acids as regulators of molecular and cellular interactions. Curr. Opin. Struct. Biol.19, 507–514. 10.1016/j.sbi.2009.06.003
36
SchmidtU.WeigertM.BroaddusC.MyersG. (2018). “Cell detection with star-convex polygons,” in Medical Image Computing and Computer Assisted Intervention—MICCAI 2018, eds Frangi AF, Schnabel JA, Davatzikos C, Alberola-López C, Fichtinger G, eds (Cham: Springer International Publishing), 265–273.
37
SchnaarR. L.Gerardy-SchahnR.HildebrandtH. (2014). Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol. Rev.94, 461–518. 10.1152/physrev.00033.2013
38
SekizarS.WilliamsA. (2019). Ex vivo slice cultures to study myelination, demyelination, and remyelination in mouse brain and spinal cord. Methods Mol. Biol.1936, 169–183. 10.1007/978-1-4939-9072-6_10
39
ShahrazA.KopatzJ.MathyR.KapplerJ.WinterD.KapoorS.et al. (2015). Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages. Sci. Rep.5, 16800. 10.1038/srep16800
40
ShahrazA.LinY.MbrohJ.WinklerJ.LiaoH.LackmannM.et al. (2022). Low molecular weight polysialic acid binds to properdin and reduces the activity of the alternative complement pathway. Sci. Rep.12, 5818. 10.1038/s41598-022-09407-2
41
SmithK. J.LassmannH. (2002). The role of nitric oxide in multiple sclerosis. Lancet Neurol.1, 232–241. 10.1016/S1474-4422(02)00102-3
42
StoppiniL.BuchsP. A.MullerD. (1991). A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods37, 173–182. 10.1016/0165-0270(91)90128-M
43
SzewczykL. M.BrozkoN.NagalskiA.RöckleI.WerneburgS.HildebrandtH.et al. (2017). ST8SIA2 promotes oligodendrocyte differentiation and the integrity of myelin and axons. Glia65, 34–49. 10.1002/glia.23048
44
ThieslerH.BeimdiekJ.HildebrandtH. (2021). Polysialic acid and Siglec-E orchestrate negative feedback regulation of microglia activation. Cell. Mol. Life Sci.78, 1637–1653. 10.1007/s00018-020-03601-z
45
ThieslerH.KüçükerdenM.GretenkortL.RöckleI.HildebrandtH. (2022). News and views on polysialic acid: From tumor progression and brain development to psychiatric disorders, neurodegeneration, myelin repair and immunomodulation. Front. Cell Dev. Biol.10, 871757. 10.3389/fcell.2022.871757
46
WerneburgS.BuettnerF. F.ErbenL.MathewsM.NeumannH.MühlenhoffM.et al. (2016). Polysialylation and lipopolysaccharide-induced shedding of E-selectin ligand-1 and neuropilin-2 by microglia and THP-1 macrophages. Glia64, 1314–1330. 10.1002/glia.23004
47
WerneburgS.FuchsH. L. S.AlbersI.BurkhardtH.GudiV.SkripuletzT.et al. (2017). Polysialylation at early stages of oligodendrocyte differentiation promotes myelin repair. J. Neurosci.37, 8131–8141. 10.1523/JNEUROSCI.1147-17.2017
48
WerneburgS.MühlenhoffM.StangelM.HildebrandtH. (2015). Polysialic acid on SynCAM 1 in NG2 cells and on neuropilin-2 in microglia is confined to intracellular pools that are rapidly depleted upon stimulation. Glia63, 1240–1255. 10.1002/glia.22815
49
WilkinsA. (2017). Cerebellar dysfunction in multiple sclerosis. Front. Neurol.8, 312. 10.3389/fneur.2017.00312
50
WostradowskiT.PrajeethC. K.GudiV.KronenbergJ.WitteS.BrieskornM.et al. (2016). In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia. J. Neuroinflamm.13, 250. 10.1186/s12974-016-0715-3
51
ZhangJ. Q.BiedermannB.NitschkeL.CrockerP. R. (2004). The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol.34, 1175–1184. 10.1002/eji.200324723
Summary
Keywords
multiple sclerosis, organotypic cerebellar slice culture, remyelination, polysialic acid (polySia), Siglec-E, microglia, neuroinflammation, immunomodulation
Citation
Schröder L-J, Thiesler H, Gretenkort L, Möllenkamp TM, Stangel M, Gudi V and Hildebrandt H (2023) Polysialic acid promotes remyelination in cerebellar slice cultures by Siglec-E-dependent modulation of microglia polarization. Front. Cell. Neurosci. 17:1207540. doi: 10.3389/fncel.2023.1207540
Received
17 April 2023
Accepted
21 June 2023
Published
10 July 2023
Volume
17 - 2023
Edited by
Shirin Hosseini, Technical University of Braunschweig, Germany
Reviewed by
Masoud Fereidoni, Ferdowsi University of Mashhad, Iran; Matthew S. Macauley, University of Alberta, Canada
Updates
Copyright
© 2023 Schröder, Thiesler, Gretenkort, Möllenkamp, Stangel, Gudi and Hildebrandt.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Herbert Hildebrandt hildebrandt.herbert@mh-hannover.de
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.